Updates

Press Release

Lupin Limited logo
Lupin LimitedLUPIN · Filed with the exchange

Lupin received U.S.

FDA final approval for its generic Pitolisant Tablets (4.45 mg & 17.8 mg), bioequivalent to Wakix®. This expands the company's product portfolio for the US market.

Read the original filing(PDF)

No comments yet. Be the first.

More from Lupin Limited

All announcements